Short Interest in Curanex Pharmaceuticals Inc (NASDAQ:CURX) Expands By 96.7%

Curanex Pharmaceuticals Inc (NASDAQ:CURX) was the target of a significant increase in short interest in the month of August. As of August 14th, there was short interest totaling 24,375 shares, an increase of 96.7% from the July 30th total of 12,389 shares. Approximately 2.6% of the company’s shares are sold short. Based on an average trading volume of 152,801 shares, the days-to-cover ratio is presently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Curanex Pharmaceuticals in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Curanex Pharmaceuticals currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Curanex Pharmaceuticals stock. Citadel Advisors LLC acquired a new stake in shares of Curanex Pharmaceuticals Inc (NASDAQ:CURX) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 64,067 shares of the company’s stock, valued at approximately $46,000.

Curanex Pharmaceuticals Price Performance

Shares of NASDAQ:CURX traded down $0.28 during trading hours on Monday, hitting $4.28. The company’s stock had a trading volume of 7,914 shares, compared to its average volume of 86,353. The firm’s fifty day moving average price is $4.49 and its 200 day moving average price is $6.55. Curanex Pharmaceuticals has a 52 week low of $3.58 and a 52 week high of $183.59. The company has a market capitalization of $6.72 million and a price-to-earnings ratio of -0.55.

Curanex Pharmaceuticals (NASDAQ:CURX) last released its quarterly earnings data on Friday, August 14th. The company reported ($2.40) earnings per share (EPS) for the quarter.

About Curanex Pharmaceuticals

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.